ABSTRACT
Background Axial Spondyloarthritis can lead to significant disability and impairment in quality of life. TNF inhibitors are recommended to patients enduring active disease despite conventional treatment. Nonetheless, up to 40% of patients of patients fail to respond to TNF inhibitors. In this context, it is important to identify as early as possible patients highly likely to respond. This study aims at identifying, among axial spondyloarthritis patients undergoing treatment with the TNF inhibitor adalimumab, early molecular biomarkers differentiating good responders from non-responders after 14 weeks of treatment, as measured by ASAS20.
Methods Peripheral blood RNA sequencing and serum proteins measured by mass spectrometry were evaluated in a cohort of biologic naïve axial spondyloarthritis patients (n = 35), before (baseline) and after (3-5 days, 2 weeks and 14 weeks) treatment with adalimumab. Results from differential expression analysis were used in combination with clinical data to build logistic regression models and random forest models to predict response to adalimumab at baseline.
Results Responders to adalimumab presented higher levels of markers of innate immunity at baseline, mostly related with neutrophils, and lower levels of adaptive immunity markers, particularly B-cells. A logistic regression model incorporating ASDAS-CRP and AFF3, the top differentially expressed gene between responders and non-responders at baseline, enabled an accurate prediction of response to adalimumab in our cohort (AUC=0.96), with random forest models suggesting 80% predictive accuracy. A treatment-associated signature suggests a reduction in inflammatory activity, with C-reactive protein and Haptoglobin showing strong and early decrease in the serum of axial spondyloarthritis patients, while a cluster of apolipoproteins showed increased expression at week 14.
Conclusions Differences in disease activity and/or blood innate/adaptive immune cell type composition at baseline may be a major contributor to response to adalimumab in axial spondyloarthritis, where a model including clinical and blood gene expression variables shows high predictive power. Our results suggest novel molecular biomarkers of response to adalimumab at baseline.
Trial registration Axial spondyloarthritis patients were selected from participants of the Bioefficacy study - Biomarkers Identification of Anti-TNFα Agent’s Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry (clinical trials.gov identifier NCT02492217).
Competing Interest Statement
F.M.P.-S. has received research grants by Abbvie, Janssen, Novartis, and received consulting fees from AbbVie, Astra Zeneca, Biogen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, Tecnimed, UCB. J.L.-G. received consulting fees from Abbvie, Pfizer. H.S. received consulting fees from Abbvie, Eli-Lilly, Novartis, Pfizer. J.T.-C. received consulting fees from AbbVie, AMGEN, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, UCB. M.B. received consulting fees from Lilly, Janssen and Abbvie. For all authors with potential conflicts of interest, these were not directly related to this study. The other authors declare that there are no conflicts of interest to disclose.
Funding Statement
D.S. was funded by a fellowship from Fundacao para a Ciencia e Tecnologia (PTDC/MED-ONC/28660/2017). This study was funded by Abbvie but the funder had no influence in study design, data analysis and writing of the submitted document.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study (registered in clinical trials.gov with the identifier NCT02492217) was approved by the national competent authorities: National Ethics Committee for Clinical Research (CEIC) and INFARMED (competent authority to regulate medicinal products). The study was conducted according to Good Clinical Practices (GCP), Declaration of Helsinki, and legal regulation applicable, ensuring participants safety and mechanisms for data protection. Written informed consent was obtained from all participants before study inclusion. None of the patient identifiers were known to anyone outside of the research group. There was no active involvement of patients or the public as co-producers of research in this project. However, all participants were invited to participate in a meeting where the main results were presented and discussed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Transcriptomics and proteomics data are available as supplementary tables in zenodo under the DOI https://doi.org/10.5281/zenodo.4914646. Mass spectrometry data are available through the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/), under dataset identifiers PXD026189 and http://doi.org/10.6019/PXD026189.
Abbreviations
- ASAS
- assessment in ankylosing spondylitis
- ASDAS
- ankylosing spondylitis disease activity score
- AUC
- area under the curve
- axSpA
- axial spondyloarthritis
- BASDAI
- bath ankylosing spondylitis disease activity index
- bDMARD
- biological disease-modifying antirheumatic drugs
- BL
- baseline
- ESR
- erythrocyte sedimentation rate
- FC
- fold change
- GSEA
- gene set enrichment analysis
- HLA-B27
- human leukocyte antigen B27
- MRI
- magnetic resonance imaging
- NSAID
- non-steroidal anti-inflammatory drugs
- PCA
- principal component analysis
- RA
- rheumatoid arthritis
- sPLS-DA
- sparse partial least squares discriminant analysis
- TNFi
- tumor necrosis factor inhibitor
- w14
- week 14
